Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05198843CT.gov Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT01471106CT.gov Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | — | Completed | — | — | — |
NCT01306942CT.gov Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | — | Completed | — | — | — |
NCT00903006CT.gov Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | — | Terminated | — | — | — |
NCT00780676CT.gov Personalized Treatment Selection for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00924352CT.gov Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00767520CT.gov Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer | — | Completed | — | — | — |
NCT00820170CT.gov Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 | — | Completed | — | — | — |
NCT00817531CT.gov Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients | — | Terminated | — | — | — |
Show 9 more trialsShow fewer
NCT00754325CT.gov Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor | — | Completed | — | — | — |
NCT00696072CT.gov Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic | — | Completed | — | — | — |
NCT00566618CT.gov Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | — | Completed | — | — | — |
NCT00546104CT.gov Phase II Dasatinib Study in Advanced Breast Cancer | — | Completed | — | — | — |
NCT00452673CT.gov Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00410813CT.gov S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone | — | Completed | — | — | — |
NCT00371254CT.gov A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer | — | Completed | — | — | — |
NCT00371345CT.gov Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer | — | Completed | — | — | — |
NCT01410708CT.gov TORI 104 Pre-Surgical Dasatinib | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dasatinib (this asset) | National Cancer Institute (NCI) | P2 | B · 58 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Dasatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 68 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dasatinib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dasatinib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →